The biotech firm reported a cash position of $1.1 billion as of March 31, up from $742.2 million at year-end 2025.
CG Oncology reported first-quarter revenue of $1.08 billion and a GAAP loss of $0.71 per share. The results reflect the company’s ongoing investment in research and development amid expansion efforts.
Cash, cash equivalents, and marketable securities totaled $1.1 billion as of March 31, 2026, compared with $742.2 million at the end of 2025. The increase includes net proceeds of approximately $391.4 million from recent financing activities.
The company did not disclose immediate market reactions or analyst expectations for the quarter.